Sugi Predict

Sugi Predict / Targets / IL2

IL2

Interleukin-2 · P60568 · IL2 on Sugi Atlas →

17,915 patent compounds predicted against IL2, 11,516 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL451062 SCHEMBL451062 0.62 15/20
SCHEMBL452378 SCHEMBL452378 0.66 14/20
SCHEMBL1702182 SCHEMBL1702182 0.58 13/20
SCHEMBL1781322 SCHEMBL1781322 0.57 13/20
SCHEMBL1828207 SCHEMBL1828207 0.63 12/20
Iodide Iodide (SCHEMBL987563) 0.51 12/20
SCHEMBL1701731 SCHEMBL1701731 0.51 12/20
SCHEMBL1701939 SCHEMBL1701939 0.58 11/20
SCHEMBL1701936 SCHEMBL1701936 0.58 11/20
SCHEMBL1702004 SCHEMBL1702004 0.49 11/20
SCHEMBL1828459 SCHEMBL1828459 0.58 10/20
SCHEMBL1701180 SCHEMBL1701180 0.51 10/20
SCHEMBL449982 SCHEMBL449982 0.63 9/20
SCHEMBL438956 SCHEMBL438956 0.48 9/20
SCHEMBL1701611 SCHEMBL1701611 0.47 9/20
SCHEMBL1782027 SCHEMBL1782027 0.43 9/20
SCHEMBL767432 SCHEMBL767432 0.39 9/20
SCHEMBL1701956 SCHEMBL1701956 0.59 8/20
SCHEMBL468853 SCHEMBL468853 0.58 8/20
SCHEMBL468855 SCHEMBL468855 0.58 8/20

Clinical trials — most relevant to IL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC PHASE2RECRUITING
Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients PHASE2COMPLETED
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) PHASE1/PHASE2RECRUITING
Efficacy of Interleukin-2 in Triple Negative Breast Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients PHASE2COMPLETED
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer PHASE2WITHDRAWN
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2 PHASE1/PHASE2SUSPENDED
A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy PHASE2COMPLETED
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer PHASE2COMPLETED
Interleukin-2 in Treating Patients With Metastatic Melanoma PHASE2UNKNOWN
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2 PHASE2COMPLETED
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma PHASE2NOT_YET_RECRUITING
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS PHASE2WITHDRAWN
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail PHASE2COMPLETED
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients PHASE2COMPLETED
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer PHASE2COMPLETED
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma PHASE1COMPLETED
Re-Stimulated TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE1ACTIVE_NOT_RECRUITING
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD PHASE1COMPLETED
Low Dose IL-2 for Ulcerative Colitis PHASE1COMPLETED
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome PHASE1COMPLETED
Ultra Low Dose Interleukin-2 in Healthy Volunteers PHASE1COMPLETED
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease PHASE1ACTIVE_NOT_RECRUITING
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals nanUNKNOWN
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer nanNOT_YET_RECRUITING
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD) nanNOT_YET_RECRUITING
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IL2 binder may also engage these)

ProteinNameSimilarity
P68291 — 1.000 P68291 →
Q865Y1 — 1.000 Q865Y1 →
Q29615 — 1.000 Q29615 →
P68290 — 1.000 P68290 →
P46649 — 1.000 P46649 →
O97513 — 1.000 O97513 →
O62641 — 1.000 O62641 →
Q29416 — 1.000 Q29416 →
Q08081 — 1.000 Q08081 →
Q9XT84 — 1.000 Q9XT84 →
Q7JFM3 — 1.000 Q7JFM3 →
Q7JFM4 — 1.000 Q7JFM4 →
Q7JFM2 — 1.000 Q7JFM2 →
P26891 — 1.000 P26891 →
P19114 — 1.000 P19114 →
Q07885 — 1.000 Q07885 →
Q2PE47 — 1.000 Q2PE47 →
Q1WM29 — 1.000 Q1WM29 →
Q9XS38 — 1.000 Q9XS38 →
Q2PE78 — 1.000 Q2PE78 →
P60569 — 1.000 P60569 →
Q95KP3 — 1.000 Q95KP3 →
Q8MKH2 — 1.000 Q8MKH2 →
Q4U313 — 1.000 Q4U313 →
P17108 — 1.000 P17108 →
O77620 — 1.000 O77620 →
Q5MBA8 — 1.000 Q5MBA8 →
Q9XT83 — 1.000 Q9XT83 →
P36835 — 1.000 P36835 →
P79155 — 1.000 P79155 →